Mastering Psoriatic Arthritis Management Guidelines for SCE Success

Psoriatic Arthritis (PsA) is a chronic, inflammatory arthritis that affects up to 30% of patients with psoriasis. It represents one of the spondyloarthritis group of disorders and is increasingly tested in the SCE Rheumatology examination. This comprehensive guide covers the essential management guidelines you need to know for exam success.

Classification and Diagnosis

The Classification Criteria for Psoriatic Arthritis (CASPAR) are essential for diagnosis. A patient must have inflammatory articular disease (joint, spine, or enthesitis) with at least 3 points from the following:

• Current psoriasis (2 points)

• History of psoriasis (1 point)

• Family history of psoriasis (1 point)

• Dactylitis (1 point)

• Nail lesions (onycholysis, pitting) (1 point)

• Rheumatoid factor negative (1 point)

• Evidence of enthesitis (1 point)

Assessment of Disease Activity

The Disease Activity index for Psoriatic Arthritis (DAPSA) is the primary tool used to assess disease activity and guide treatment decisions:

• DAPSA remission: ≤4

• Low disease activity: 5-14

• Moderate disease activity: 15-28

• High disease activity: >28

Other assessment tools include the Minimal Disease Activity (MDA) criteria and the Psoriasis Area and Severity Index (PASI) for skin involvement.

Treatment Approach: The Treat-to-Target Strategy

The fundamental principle of PsA management is a treat-to-target approach, aiming for remission or minimal disease activity.

First-Line Therapy

Conventional synthetic DMARDs:

• Methotrexate is first-line for polyarticular PsA, particularly with significant skin involvement

• Start at 15mg weekly, titrate to 25mg weekly

• Monitor LFTs and full blood count regularly

• Folic acid 5-10mg weekly, 24-48 hours after methotrexate

Second-Line Therapy (Biologics)

If the patient has poor prognostic factors (elevated ESR/CRP, erosive disease, significant functional impairment) or inadequate response to csDMARDs:

TNF inhibitors (first-line biologic):

• Etanercept, Adalimumab, Infliximab, Certolizumab, Golimumab

• Fast onset of action

• Effective for both arthritis and skin disease

IL-17 inhibitors:

• Secukinumab, Ixekizumab

• Particularly effective for enthesitis and axial disease

• Also excellent for skin psoriasis

IL-12/23 inhibitor:

• Ustekinumab

• Good for concomitant severe psoriasis

Third-Line Therapy (Targeted Synthetic DMARDs)

JAK inhibitors:

• Tofacitinib, Upadacitinib

• Oral agents, useful for multiple domains of disease

• Consider cardiovascular and malignancy risk stratification

Management of Specific Domains

Enthesitis

Enthesitis is a hallmark of PsA. Treatment options include:

• NSAIDs as first-line

• Local corticosteroid injections

• TNF inhibitors or IL-17 inhibitors for refractory cases

Axial Disease

For axial involvement:

• TNF inhibitors or IL-17 inhibitors are preferred

• Secukinumab and ixekizumab have strong evidence

• Physical therapy and regular exercise are crucial

Dactylitis

• Usually responds well to systemic therapy

• Local corticosteroid injections can be considered

• TNF inhibitors are highly effective

Skin and Nail Disease

• Close liaison with dermatology is recommended

• Methotrexate, biologics (especially IL-17 and IL-12/23 inhibitors) are effective

• Topical treatments for mild disease

Monitoring and Follow-up

Regular assessment should include:

• Joint examination for swollen and tender joints

• Enthesitis assessment (Leeds Enthesitis Index)

• Skin PASI scoring

• Patient-reported outcomes (quality of life, functional status)

• Inflammatory markers (ESR, CRP)

SCE Exam Key Points

1. CASPAR criteria are essential – know the scoring system

2. DAPSA is the preferred disease activity measure

3. Treat-to-target strategy with goal of minimal disease activity or remission

4. Methotrexate remains first-line csDMARD

5. TNF inhibitors are first-line biologic therapy

6. IL-17 inhibitors (secukinumab, ixekizumab) are particularly effective for enthesitis and skin disease

7. JAK inhibitors are oral options for refractory disease

8. Multidisciplinary approach with dermatology is emphasized

9. Cardiovascular risk management is important due to increased cardiovascular mortality

10. Smoking cessation and lifestyle modifications are recommended

Recent Guideline Updates

The 2024 EULAR and GRAPPA guidelines emphasize:

• Early aggressive treatment with biologic DMARDs for patients with poor prognostic factors

• IL-17 and IL-23 inhibitors have expanded roles

• Tapering of biologic therapy may be considered in sustained remission

• Biosimilars are recommended to improve cost-effectiveness

Conclusion

Psoriatic Arthritis management has evolved significantly with the advent of biologic therapies. For the SCE exam, focus on understanding the treatment algorithm, knowing the different biologic classes and their indications, and being familiar with disease activity assessment tools. The key is to demonstrate a systematic approach to diagnosis and management following current evidence-based guidelines.

Remember: A holistic approach addressing musculoskeletal, skin, and psychological aspects, along with cardiovascular risk management, is essential for comprehensive PsA care.